Holliston biotech Biostage is on the cusp of an important milestone as it prepares to file an investigational new drug application with the hope of launching clinical trials for an implant intended to treat a rare esophagus condition.
Holliston biotech Biostage said Tuesday it plans to file with the U.S. Food & Drug Administration in September to kick-start the company’s clinical trials of its esophagus implant.